| Name | Title | Contact Details |
|---|
Payfare is a global FinTech company offering mobile banking, instant payment and loyalty-reward solutions for today`s workforce. Payfare`s financial technology platform is providing financial inclusion and empowerment to millions of next-generation workers around the globe with a full-service mobile bank account and debit card with instant access to their earnings and relevant cash-back rewards. Payfare was founded in 2015 by fintech entrepreneurs and a senior management team with unparalleled experience in the banking, payment card and financial technology sectors. Payfare is backed by major investors and financial institutions around the world. The company is headquartered in Toronto, Canada. Some of the world`s largest on-demand economy platforms including Uber, Lyft, DoorDash and DiDi trust Payfare to pay their workers.
Headquartered in Los Angeles, California, Manufacturers Bank is a wholly owned subsidiary of SMBC Americas Holding, Inc., a member of SMBC Group. For over 60 years, the Commercial Bank division of Manufacturers Bank has been serving middle-market and corporate businesses by providing sophisticated solutions and expertise with the personal touch of a community bank. The Commercial Bank division serves the specialized needs of middle-market and corporate businesses, franchise finance including quick service restaurants, manufacturers, wholesalers, distributors, importers, exporters, and service companies. We offer a comprehensive suite of credit, deposit and treasury management solutions including foreign exchange and trade finance. The Commercial Bank has offices in Los Angeles, Beverly Hills, Brea, Encino, Glendale, Newport Beach, San Jose, and Torrance. Member FDIC
We are a Performance Improvement Consulting Firm Increase profitability and productivity with our proven Management System™. It is an accountability system that creates focus and alignment driving breakthrough results for your business. WHY WORK WITH US? 1. RESULTS Over 15,000 organizations and 170,000 business leaders accelerated their leadership and management performance through our proven MAP Management System™. 2. EXPERIENCE Our consultants are former CEOs and entrepreneurs with a track record of success who work with you every step of the way on business strategy and implementation. 3. LONGEVITY Weve been around since 1960 and worked on an incredibly diverse range of challenges across all industries and sizes. Are you ready to take your business to the next level?
Based in Austin, Texas, TimberTown Specialty Building Products supplies high quality lumber and building materials for a wide variety of residential and commercial projects. Our products range from high-end exotic hardwoods, softwoods and composites; often specially milled for different applications. The types of projects we supply can be as simple as a small residential outdoor cedar deck, to the very complex hardwood siding for a multi-million dollar custom home or a rooftop patio on a downtown high-rise. With such a large and diverse client base, we excel in providing exceptional service for contractors and commercial builders, architects, designers and their clients.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.